Research topics & objectivesThe laboratory aims to establish tumour models of resistance in vitro and/or in vivo to monoclonal antibodies and to characterise the models thus obtained in order to develop new therapeutic treatments (in combination or in monotherapy).
Study of the action mechanisms of monoclonal antibodies directed against cancer cells, as well as mechanisms of resistance to these biomolecules, in order to optimise monoclonal antibody-based treatments for patients suffering from blood diseases or solid tumours.
- Mouse B-cell lymphoma
- Burkitt lymphomas
- Follicular lymphomas
- Diffuse large B-cell lymphomas
Screening, Anticancer agent, Lymphoma, Preclinical models
BIOLOGICAL TARGETS AND IN VITRO/IN VIVO/EX VIVO MODELS
CD20, immunes checkpoints
- In vitro models resistant to Idealisib and Ibrutinib
- In vivo syngeneic and xenografted models
- ADCC/CDC models
- Validated models of resistance to GA101 and Rituximab and models of resistance to R-CHOP currently being established, resistance to immune checkpoint inhibitors (anti-PD1) currently being established
- ALL, AML, CML, myeloma and NHL ex vivo samples
BLOOD AND TISSUE BIOMARKERS
Phosphoprotein analysis through cytometry, functional tests (ADCC, ADCP).
Platforms & technical resources
Privileged access to the Rockfeller animal collection, partnership with the platforms ProfilXpert (micro-genomics and genomics platform), Anipath (rodent histology centre), Imthernat (imaging centre for small laboratory animals), Antineo (CRO for the development of innovating anticancer agents).
Preclinical evaluation of biological composites (efficacy / toxicity, in combination and/or monotherapy) through in vivo and in vitro resistance models from the laboratory.